News
17 July 2024

JBIC funds Ajinomoto's deal to buy US gene therapy group Forge

In:
Infrastructure
Region:
Asia-Pacific

JBIC has agreed a loan of up to JPY57 billion (just over $362 million) with Ajinomoto to allow the Japanese biotech company to acquire US-based Forge Biologics Holdings. The co-financing amount is JPY97 billion.Through the deal, Ajinomoto aims to combine Forge's gene therapy CDMO platform with...

Exclusive subscriber content…

If you are a TXF subscriber, please login to continue reading

Login

Not yet a subscriber? Join us today to continue accessing content without any restrictions

View our subscription options

Or to request access to TXF Intelligence contact us

Request Access

You might also like


Perspective
06 September 2024

If I had a nickel

ECAs, DFIs and banks to Madagascar’s Ambatovy nickel mine project financing are facing a wipe out of $1.66 billion loans under a new shareholder restructuring proposal. Though...

Expert opinion
12 September 2024

EDC’s Lavery on creating a legacy of no wrong doors to...

Mairead Lavery at EDC is coming to the end of her term as CEO. She discusses changes in her philosophy, the need for reform of Common Approaches, and creating a robust Bretton...